The challenges of rapid clinical diagnosis to combat antibiotic resistance
According to the WHO, antibiotic resistance constitutes one of the greatest threats to global public health today. More and more infections are becoming difficult to treat as antibiotics lose their effectiveness. Among the challenges in combating antibiotic resistance, rapid clinical diagnosis plays an essential role in the proper use of antibiotics.
Through this biorezo, the Eurobiomed cluster wishes to give a voice to a few actors (clinicians, researchers, industrialists) engaged in this fight.
Programme
- Opening and presentation of the Eurobiomed center
- Emmanuel LE BOUDER – Innovation Director – Eurobiomed
- The challenges of antibiotic resistance in the treatment of patients in hospital
- Pr Guillaume MARTIN-BLONDEL
Department of Infectious and Tropical Diseases, Toulouse University Hospital - Pr Eric OSWALD
Head of the Bacteriology-Hygiene department, Toulouse University Hospital - Dr Damien DUBOIS
Bacteriology-Hygiene Laboratory – Federal Institute of Biology – Toulouse University Hospital
- Pr Guillaume MARTIN-BLONDEL
- Presentation of some technological solutions developed by companies at the heart of the fight against multi-resistant bacteria.
- I2A: The rapid, dynamic and targeted antibiogram
Arnaud SERFASS, CEO & Michel Roch, Directeur R&D - WEEZION: Identification and profile of antibiotic resistance by targeted mass spectrometry in less than 90 minutes
François VANDENESCH and Jérôme LEMOINE, co-founders and partners, Hervé BROCHETTE, CEO - BIOMERIEUX: Improvement in the management of Sepsis: how to reduce the time to optimize treatment?
Romuald COURTADE, EME Microbiology Marketing Director and Martina HNATOVA, BioFire France Market Manager
- I2A: The rapid, dynamic and targeted antibiogram
For more information : Leila TOUIHRI
Free but required registration: ICI
This event is organized in partnership with: